Form 4: Director Receives 10,000 Restricted Stock Units

H. Lawrence Remmel, a Director at Atossa Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on May 12, 2026, which will vest one year later.

Summary

• H. Lawrence Remmel, a Director of Atossa Therapeutics, Inc., received a grant of 10,000 Restricted Stock Units (RSUs) on May 12, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs are scheduled to vest on the first anniversary of the grant date, May 12, 2027.
• Following this transaction, Mr. Remmel beneficially owns 10,683 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard equity grant to a director, which is a routine event and does not inherently signal positive or negative performance.

Positives

• Director H. Lawrence Remmel received a grant of 10,000 RSUs, indicating a form of equity-based compensation or incentive.
• The RSUs vest in one year, aligning the director's interests with long-term shareholder value.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance or strategic initiatives. It solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that grants of Restricted Stock Units (RSUs) to directors are a common practice in the biotechnology and pharmaceutical sectors, aligning executive compensation with company performance and long-term value creation. This type of award is standard for incentivizing leadership in companies like Atossa Therapeutics.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director is a standard compensation practice that aligns director interests with long-term shareholder value. The vesting schedule encourages sustained commitment.
• Employees: This filing does not directly impact employees, but it reflects standard executive compensation practices within the company.
• Management: The grant serves as an incentive for the director to contribute to the company's success.

Next Steps

• The RSUs will vest on May 12, 2027.
• The director's beneficial ownership will be updated upon vesting or any subsequent transactions.

Key Dates

Keywords

Atossa Therapeutics, ATOS, Form 4, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Beneficial Ownership